CONTROLLED RELEASE ORAL DOSAGE FORMS OF POORLY SOLUBLE DRUGS AND USES THEREOF
Provided herein are controlled release oral dosage forms of poorly soluble drugs, methods of making the dosage forms, and methods of their use for the treatment of various diseases and/or disorders.
1 . A controlled release oral dosage form comprising:
(i) a poorly soluble drug;
(ii) a swelling excipient;
(iii) a cationic polymer in acidic pH; and
(iv) an anionic polymer in acidic pH.
2 . The controlled release oral dosage form of claim 1 which further comprises a water absorbing agent.
3 . The controlled release oral dosage form of claim 1 which further comprises a disintegrant.
4 . The controlled release oral dosage form of claim 3 , wherein the disintegrant is lactose, microcrystalline cellulose, sodium starch glycolate or sodium crosscarmellose.
5 . The controlled release oral dosage form of claim 1 , wherein the swelling excipient is hydroxyethylcellulose, carboxymethylcellulose or polyethylene oxide.
6 . The controlled release oral dosage form of claim 1 , wherein the cationic polymer in acidic pH is chitosan, methacrylic acid—methyl methacrylate copolymer, or poly(butyl methacylate-co-2-dimethylaminoethyl methacrylate-co-methyl methacrylate) (1:2:1).
7 . The controlled release oral dosage form of claim 6 , wherein the chitosan has an average molecular weight of about 10,000 to about 5,000,000 Da.
8 . The controlled release oral dosage form of claim 6 , wherein the chitosan has an average molecular weight of about 10,000 to about 2,000,000 Da.
9 . The controlled release oral dosage form of claim 6 , wherein the chitosan has a degree of deacylation of at least 70%.
10 . The controlled release oral dosage form of claim 6 , wherein the chitosan has a degree of deacylation of at least 90%.
11 . The controlled release oral dosage form of claim 1 , wherein the anionic polymer in acidic pH is an alginate.
12 . The controlled release oral dosage form of claim 11 , wherein the aginate is sodium alginate.
13 . The controlled release oral dosage form of claim 1 , wherein the anionic polymer in acidic pH is carrageenan or a salt of carboxymethyl cellulose.
14 . The controlled release oral dosage form of claim 1 , wherein the poorly soluble drug is a compound of formula (I):
15 . The controlled release oral dosage form of claim 1 , wherein the poorly soluble drug is a compound of formula (II):
16 . The controlled release oral dosage form of claim 1 , wherein the dosage form consists of about 10% by weight of the compound of formula (I):
about 36% by weight of polyethylene oxide, about 15% by weight of sodium chloride, about 4% by weight of chitosan, about 15% by weight of sodium alginate, about 12.5% by weight of lactose, about 7% by weight of sodium crosscarmellose, and about 0.5% by weight of magnesium stearate.
17 . The controlled release oral dosage form of claim 1 , wherein the dosage form consists of about 10% by weight of the compound of formula (I):
about 36% by weight of sodium carboxymethyl cellulose, about 15% by weight of sodium chloride, about 4% by weight of chitosan, about 15% by weight of sodium alginate, about 12.5% by weight of lactose, about 7% by weight of sodium crosscarmellose, and about 0.5% by weight of magnesium stearate.
18 . The controlled release oral dosage form of claim 1 , wherein the dosage form consists of about 10% by weight of the compound of formula (I):
about 50% by weight of polyethylene oxide, about 11.5% by weight of lactose, about 14% by weight of sodium alginate, about 14% by weight of carrageenan, and about 0.5% by weight of magnesium stearate.
19 . The controlled release oral dosage form of claim 1 , wherein the dosage form consists of about 10% by weight of the compound of formula (I):
about 36% by weight of polyethylene oxide, about 11.5% by weight of lactose, about 14% by weight of sodium alginate, about 14% by weight of chitosan, about 14% by weight of hydroxyethylcellulose, and about 0.5% by weight of magnesium stearate.
20 . The controlled release oral dosage form of claim 1 , wherein the dosage form consists of about 20% by weight of the compound of formula (I):
about 32.8% by weight of polyethylene oxide, about 10.4% by weight of sodium chloride, about 12% by weight of chitosan, about 8.4% by weight of sodium alginate, about 8.4% by weight of hydroxyethylcellulose, about 7.6% by weight of microcrystalline cellulose, and about 0.4% by weight of magnesium stearate.
21 . The controlled release oral dosage form of claim 1 , wherein the dosage form consists of about 20% by weight of the compound of formula (I):
about 34% by weight of polyethylene oxide, about 12% by weight of sodium chloride, about 13.2% by weight of chitosan, about 7.6% by weight of sodium alginate, about 12.8% by weight of hydroxyethylcellulose, and about 0.4% by weight of magnesium stearate.
22 . The controlled release oral dosage form of claim 1 , wherein the dosage form consists of about 20% by weight of the compound of formula (I):
about 34% by weight of polyethylene oxide, about 12% by weight of sodium chloride, about 13.2% by weight of poly(butyl methacylate-co-2-dimethylaminoethyl methacrylate-co-methyl methacrylate) (1:2:1), about 7.6% by weight of sodium alginate, about 12.8% by weight of hydroxyethylcellulose, and about 0.4% by weight of magnesium stearate.
23 . The controlled release oral dosage form of claim 1 , wherein the dosage form consists of about 20% by weight of the compound of formula (I):
about 34% by weight of polyethylene oxide, about 6% by weight of sodium chloride, about 13.2% by weight of poly(butyl methacylate-co-2-dimethylaminoethyl methacrylate-co-methyl methacrylate) (1:2:1), about 8% by weight of lactose, about 7.6% by weight of sodium carboxymethyl cellulose, about 10.8% by weight of hydroxyethylcellulose, and about 0.4% by weight of magnesium stearate.